All News

2 year guselkumab data from Discover-2 @DrLauraCoates et al. Continue incremental improvements across all key domains through 2 years of treatment @RheumNow #EULAR2022 POS1017 https://t.co/wcSKCID9Yt

☄️ Biomarkers substudies of COSMOS & DISCOVER-1 RCT GUS in PsA: TNFi-IR pts have a different plasma signature w/ higher BL IL-22 & TNF *Association between BL IL-22 levels & W24 PASI75 and trend for BL IL-22 levels & W24 ACR20 #EULAR2022 @RheumNow POS0074 @StefanSiebert1 https://t.co/Midtug4NJO

Dr. K Hyrich who/when to vaccinate. #EULAR2022 @rheumnow https://t.co/40y9ngJnbW

#Vaccine disparities globally #EULAR2022 @rheumnow https://t.co/w12ok1Y1b5

Kimme Hydrich: There is no increased of "exceedingly rare" vaccination adverse effects in rheumatic patients 💉APLS is NOT a risk factor for thrombotic AEs with vaccination #EULAR2022 @Rheumnow @rheum_covid

HAS-GCA study @alwinuk @profbdasgupta Southend pretest probability score and Halo score useful in diagnosis and prognosis in GCA. Halo score may be useful for monitoring. @RheumNow #EULAR2022 POS0818 https://t.co/sxYjnQQFA8

Do you vaccine pts w/ RMDs for shingles? If so, when and who and with what? @khyrich highlights differences in recommendations and contra-indications across countries #EULAR2022 @RheumNow https://t.co/c0uvOPopF4

“One of the benefits of #vaccinations people don’t talk about is the relief they feel after vaccination." - Dr E Hyrich #EULAR2022 @rheumnow

RheumNow’s coverage of the #EULAR2022 Annual meeting is sponsored in part by Bristol-Myers Squibb. All content is chosen by RheumNow & its Faculty.

💫Trajectory analysis in SpA💫 Data on 1,125 patients Prediction of spinal radiographic progression ⭐️FAST associated w/ onset at older age & 👁involvement ⭐️SLOW progression associated w/ female gender & peripheral involvement. #EULAR2022 @RheumNow OP0151 https://t.co/E80qCLEtBv

Preito-Pena at al. Tocilizumab in LVV-GCA and TAK. Similar responses in both, with 75% showing complete clinical response but only 20% complete imaging response at month 12. Clinical implications of these persistent imaging findings need clarification @RheumNow #EULAR2022 POS0804 https://t.co/sNbRzIkwnt

#EULAR2022 "The mRNA vaccines are simple to make." - Saul Faust The key step is encapsulation in lipid to allow for take up by cell. 💉💉💉 @RheumNow https://t.co/T2ZxF6bLV5

Comorbidity in AS from @rheum_cat , Karmacharya et al. Clustering of comorbidities. Depression and hypertension clusters assoc worse disease activity and function @RheumNow #EULAR2022 OP0154 https://t.co/jGQXayAYs9 https://t.co/SnVDhVYQq5

EULAR Abstract Archive

Flatman et al. Serious infections in babies born to women using TNFi during pregnancy. 2902 babies. Adjusted HR 1.20 (0.54-2.64) for agents with high vs low placental transfer. @RheumNow #EULAR2022 OP0130 https://t.co/oaW7wDPxva

EULAR Abstract Archive

#EULAR2022 OP0134: Active RA increases risk of dementia Olmsted County, MINN studying RA risk factors for dementia: ⭐️886 pts incident RA, mean age 65. 103 develop dementia Risk factors: Age, rheum nodules, large jt swelling, depression/anxiety, HTN, CVD events @Rheumnow https://t.co/bUFkzBovAy

Fonzetti et al. Isolated Ro-52 in pSS. 300 patients. Less inflammatory features but more fibrotic disease - ILD and PBC. @RheumNow #EULAR2022 OP0146 https://t.co/2WIAu8qKiH https://t.co/mspSBNxbx2

EULAR Abstract Archive

Prof T Dorner summarizes what's new in #SLE #EULAR2022 @rheumnow https://t.co/YT0Ocw7I41

Large collaborative study on IIM treatment patterns from @Nellziade @ElenaNikiUK @LatikaGupta_ @drhectorchinoy @MarcinMilchert and many others. Significant geographic differences, highlighting need for consensus guidelines @RheumNow #EULAR2022 OP0161 https://t.co/osaORtgvxh https://t.co/96PypMtlcl

EULAR Abstract Archive

#EULAR2022 OP0138: BIOBADASER registry: Cancer risk in AI disease after bDMARD & tsDMARD + h/o prior malignancy ⭐️352 pts w prior malignancy in registry, 32 developed a 2nd incident malignancy 27 rate of cancer/1000 patient years. No diff of cancer or mortality b/w Rx @Rheumnow https://t.co/nTuUooBmzV

Ghalandari et al EUDRAVIGILANCE database congenital malformations for non-TNFi bDMARDs (vs certolizumab). ORs suggest possible B-cell modulators and vedolizumab, not others. Geneticist rvw no pattern for B-cell agents. @RheumNow #EULAR2022 OP0129 https://t.co/nrj8MxjAri https://t.co/p6JkfjjtdH

EULAR Abstract Archive

Topics

All News

Do you get our email newsletter?